William C. Zamboni, Ph.D.
Affiliations: | 2005 | University of Pittsburgh, Pittsburgh, PA, United States |
Area:
PharmacologyGoogle:
"William Zamboni"Mean distance: (not calculated yet)
Parents
Sign in to add mentor| Raman Venkataramanan | grad student | 2005 | University of Pittsburgh | |
| (Preclinical and clinical pharmacologic studies of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Moody AS, Dayton PA, Zamboni WC. (2021) Imaging methods to evaluate tumor microenvironment factors affecting nanoparticle drug delivery and antitumor response. Cancer Drug Resistance (Alhambra, Calif.). 4: 382-413 |
| Piha-Paul SA, Thein KZ, De Souza P, et al. (2021) First-in-human, phase I/IIa study of CRLX301, a nanoparticle drug conjugate containing docetaxel, in patients with advanced or metastatic solid malignancies. Investigational New Drugs |
| Price LSL, Stern ST, Deal AM, et al. (2020) A reanalysis of nanoparticle tumor delivery using classical pharmacokinetic metrics. Science Advances. 6: eaay9249 |
| Graham-Gurysh EG, Moore KM, Schorzman AN, et al. (2020) Tumor Responsive and Tunable Polymeric Platform for Optimized Delivery of Paclitaxel to Treat Glioblastoma. Acs Applied Materials & Interfaces |
| Lucas AT, Robinson R, Schorzman AN, et al. (2019) Pharmacologic Considerations in the Disposition of Antibodies and Antibody-Drug Conjugates in Preclinical Models and in Patients. Antibodies (Basel, Switzerland). 8 |
| Wu H, Infante JR, Keedy VL, et al. (2019) Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors [Corrigendum] International Journal of Nanomedicine. 14: 5751-5752 |
| Parker CL, McSweeney MD, Lucas AT, et al. (2019) Pretargeted delivery of PEG-coated drug carriers to breast tumors using multivalent, bispecific antibody against polyethylene glycol and HER2. Nanomedicine : Nanotechnology, Biology, and Medicine. 102076 |
| Taylor SE, Petschauer JS, Donovan H, et al. (2019) Phase I study of intravenous oxaliplatin and intraperitoneal docetaxel in recurrent ovarian cancer. International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society. 29: 147-152 |
| Johannessen LH, Hu S, Ke N, et al. (2019) Abstract C091: Preclinical evaluation of PK, PD, and antitumor activity of the oral, non-covalent, potent and highly selective CDK7 inhibitor, SY-5609, provides rationale for clinical development in multiple solid tumor indications Molecular Cancer Therapeutics. 18 |
| Hwang D, Dismuke T, Rosen E, et al. (2019) SCIDOT-03. HYPERLOADED POLY(2-OXAZOLINE) MICELLES AS PERSONALIZED DRUG CARRIERS FOR BRAIN TUMORS Neuro-Oncology. 21: vi272-vi273 |